Jochen Kammermeier

Jochen Kammermeier

Auto-generated profile, based on publicly available information

Jochen Kammermeier

Pediatric Gastroenterology, Evelina London Children's Hospital, London, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2014 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
JKJochen Kammermeier
Jochen Kammermeier
SDSuzanne Drury
Suzanne Drury
CJChela T James
Chela T James
RDRobert Dziubak
Robert Dziubak
LOLouise Ocaka
Louise Ocaka
NSNeil Shah
Neil Shah
Background Multiple monogenetic conditions with partially overlapping phenotypes can present with inflammatory bowel disease (IBD)-like intestinal inflammation. With novel genotype-specific therapies emerging, establishing a molecular diagnosis is becoming increasingly important. Design We have introduced targeted next-generation sequencing (NGS) technology as a prospective screening tool in children with very early onset IBD (VEOIBD). We evaluated the coverage of 40 VEOIBD genes in two separate cohorts undergoing targeted gene panel sequencing (TGPS) (n=25) and whole exome sequencing (WES) (n=20). Results TGPS revealed causative mutations in four genes (IL10RA, EPCAM, TTC37 and SKIV2L) discovered unexpected phenotypes and directly influenced clinical decision making by supporting as well as avoiding haematopoietic stem cell transplantation. TGPS resulted in significantly higher median coverage when compared with WES, fewer coverage deficiencies and improved variant detection across established VEOIBD genes. Conclusions Excluding or confirming known VEOIBD genotypes should be considered early in the disease course in all cases of therapy-refractory VEOIBD, as it can have a direct impact on patient management. To combine both described NGS technologies would compensate for the limitations of WES for disease-specific application while offering the opportunity for novel gene discovery in the research setting.

1 March 2022 in Gastroenterology
Verified
Journal Article
Closed access
CBChrissy Bolton
Chrissy Bolton
CSChristopher S. Smillie
Christopher S. Smillie
SPSumeet Pandey
Sumeet Pandey
RERasa Elmentaite
Rasa Elmentaite
GWGabrielle Wei
Gabrielle Wei
HUHolm H. Uhlig
Holm H. Uhlig


3 October 2023 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
HUHolm H. Uhlig
Holm H. Uhlig
CBClaire Booth
Claire Booth
JCJudy Cho
Judy Cho
MDMarla Dubinsky
Marla Dubinsky
AGAnne M. Griffiths
Anne M. Griffiths
AMAleixo M. Muise
Aleixo M. Muise

1 September 2020 in Gut
Verified
Journal Article
Open access
PDF file
RHRichard Hansen
Richard Hansen
SMSusanna Meade
Susanna Meade
RBR Mark Beattie
R Mark Beattie
MAMarcus Kh Auth
Marcus Kh Auth
NCNick Croft
Nick Croft
JKJochen Kammermeier
Jochen Kammermeier
Objective Paediatric acute severe colitis (ASC) management during the novel SARS-CoV-2/COVID-19 pandemic is challenging due to reliance on immunosuppression and the potential for surgery. We aimed to provide COVID-19-specific guidance using the European Crohn’s and Colitis Organisation/European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines for comparison. Design We convened a RAND appropriateness panel comprising 14 paediatric gastroenterologists and paediatric experts in surgery, rheumatology, respiratory and infectious diseases. Panellists rated the appropriateness of interventions for ASC in the context of the COVID-19 pandemic. Results were discussed at a moderated meeting prior to a second survey. Results Panellists recommended patients with ASC have a SARS-CoV-2 swab and expedited biological screening on admission and should be isolated. A positive swab should trigger discussion with a COVID-19 specialist. Sigmoidoscopy was recommended prior to escalation to second-line therapy or colectomy. Methylprednisolone was considered appropriate first-line management in all, including those with symptomatic COVID-19. Thromboprophylaxis was also recommended in all. In patients requiring second-line therapy, infliximab was considered appropriate irrespective of SARS-CoV-2 status. Delaying colectomy due to SARS-CoV-2 infection was considered inappropriate. Corticosteroid tapering over 8–10 weeks was deemed appropriate for all. After successful corticosteroid rescue, thiopurine maintenance was rated appropriate in patients with negative SARS-CoV-2 swab and asymptomatic patients with positive swab but uncertain in symptomatic COVID-19. Conclusion Our COVID-19-specific adaptations to paediatric ASC guidelines using a RAND panel generally support existing recommendations, particularly the use of corticosteroids and escalation to infliximab, irrespective of SARS-CoV-2 status. Consideration of routine prophylactic anticoagulation was recommended.

24 May 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
FTFranco Torrente
Franco Torrente
SMSusanna Meade
Susanna Meade
EBEric I Benchimol
Eric I Benchimol
LRLissy de Ridder
Lissy de Ridder
NCNicholas M Croft
Nicholas M Croft
RHRichard Hansen
Richard Hansen
Background and Aims: Thromboprophylaxis use in paediatric inflammatory bowel disease [IBD] is inconsistent. Current guidelines only support treating children with acute severe colitis with risk factors. We convened an international RAND panel to explore thromboprophylaxis in paediatric IBD inpatients in the context of new evidence. Methods: We convened a geographically diverse 14-person panel of paediatric gastroenterologists alongside supporting experts. An online survey was sent before an online meeting. Panellists were asked to rate the appropriateness of thromboprophylaxis in hospitalised paediatric IBD patients via 27 scenarios of varying ages, gender, and phenotype, with and without thrombotic risk factors. Anonymised results were presented at the meeting. A second modified survey was distributed to all panellists present at the meeting. Results from the second survey constitute the RAND panel results. The validated RAND disagreement index defined disagreement when ≥ 1. Results: The combined outcome of thromboprophylaxis being considered appropriate until discharge and inappropriate to withhold was seen in 20 of 27 scenarios, including: all patients with new-onset acute severe colitis; all flares of known ulcerative colitis, irrespective of risk factors except in pre-pubescent patients with limited disease and no risk factors; and all Crohn’s patients with risk factors. Disagreement was seen in five scenarios regarding Crohn’s without risk factors, where outcomes were already uncertain. Conclusions: RAND panels are an established method to assess expert opinion in areas of limited evidence. This work therefore constitutes neither a guideline nor a consensus; however, the findings suggest a need to re-evaluate the role of thromboprophylaxis in future guidelines.